Home
PTGX
PTGX News

Latest Protagonist Therapeutics Inc. (PTGX) News on August 29, 2025

ACCESS Newswire

2 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Argus Research

2 months ago

PTGX: Lowering target price to $56.00

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

Insider Monkey

2 months ago

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Insider Monkey

2 months ago

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

MT Newswires

2 months ago

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target

Argus Research

3 months ago

PTGX: Rating decreased to a HOLD

For Patients With Rare Blood Cancer, New Drug Offers Relief

The Wall Street Journal

3 months ago

For Patients With Rare Blood Cancer, New Drug Offers Relief

Exploring Three High Growth Tech Stocks In The US Market

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks In The US Market

MT Newswires

3 months ago

Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint

Business Wire

3 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

Insider Monkey

3 months ago

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

ACCESS Newswire

3 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Argus Research

4 months ago

PTGX: Raising target price to $49.00

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Insider Monkey

4 months ago

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

MT Newswires

4 months ago

Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study

ACCESS Newswire

4 months ago

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Simply Wall St.

4 months ago

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Argus Research

4 months ago

PTGX: Rating increased to a BUY

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

ACCESS Newswire

4 months ago

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

ACCESS Newswire

4 months ago

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Argus Research

4 months ago

PTGX: Lowering target price to $48.00

ACCESS Newswire

4 months ago

Protagonist Therapeutics Reports Granting of Inducement Award

Argus Research

4 months ago

PTGX: Raising target price to $49.00

ACCESS Newswire

5 months ago

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Argus Research

5 months ago

PTGX: Lowering target price to $44.00

Argus Research

5 months ago

PTGX: Lowering target price to $49.00

Argus Research

5 months ago

PTGX: Lowering target price to $54.00

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Zacks

5 months ago

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Insider Monkey

5 months ago

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

FastCompany

5 months ago

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

ACCESS Newswire

5 months ago

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Insider Monkey

5 months ago

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Zacks

6 months ago

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

Zacks

6 months ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

Zacks

6 months ago

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

MT Newswires

6 months ago

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

GuruFocus.com

6 months ago

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Clinical Trials Arena

6 months ago

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Insider Monkey

6 months ago

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Investor's Business Daily

6 months ago

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

MT Newswires

6 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires

6 months ago

Top Midday Gainers

MT Newswires

6 months ago

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating

MT Newswires

6 months ago

Protagonist, Johnson & Johnson Say Phase 2b Icotrokinra Study Meets Primary Endpoint in Ulcerative Colitis

ACCESS Newswire

6 months ago

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

ACCESS Newswire

6 months ago

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Argus Research

6 months ago

PTGX: Rating decreased to a SELL

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Simply Wall St.

6 months ago

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga

6 months ago

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide

Clinical Trials Arena

6 months ago

Takeda and Protagonist report topline outcomes from trial of rusfertide

MT Newswires

6 months ago

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Business Wire

6 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

BioPharma Dive

6 months ago

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Argus Research

6 months ago

PTGX: Lowering target price to $37.00

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Simply Wall St.

6 months ago

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Zacks

6 months ago

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Associated Press Finance

6 months ago

Protagonist Therapeutics: Q4 Earnings Snapshot

MT Newswires

6 months ago

Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise

ACCESS Newswire

6 months ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Argus Research

6 months ago

PTGX: Raising target price to $40.00

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

Insider Monkey

7 months ago

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

Argus Research

7 months ago

PTGX: Lowering target price to $39.00

Biotech walks a 'tightrope' amid unclear funding, regulations

Yahoo Finance Video

7 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ACCESS Newswire

7 months ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

Argus Research

7 months ago

PTGX: What does Argus have to say about PTGX?

Argus Research

7 months ago

PTGX: Raising target price to $40.00

Argus Research

7 months ago

PTGX: Lowering target price to $39.00

ACCESSWIRE

8 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Argus Research

8 months ago

PTGX: What does Argus have to say about PTGX?

ACCESSWIRE

8 months ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Argus Research

8 months ago

PTGX: Lowering target price to $43.00

Argus Research

9 months ago

PTGX: Raising target price to $44.00

ACCESSWIRE

9 months ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

MT Newswires

9 months ago

Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

TipRanks

9 months ago

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

Argus Research

9 months ago

PTGX: Lowering target price to $43.00

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

9 months ago

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 11/29/2024

MT Newswires

9 months ago

Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing

MT Newswires

9 months ago

Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing

MT Newswires

9 months ago

Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing

Argus Research

9 months ago

PTGX: Raising target price to $47.00

ACCESSWIRE

9 months ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

ACCESSWIRE

9 months ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE

9 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE

9 months ago

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Zacks

10 months ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Argus Research

10 months ago

PTGX: Lowering target price to $45.00

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

10 months ago

Protagonist Therapeutics: Q3 Earnings Snapshot

ACCESSWIRE

10 months ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Argus Research

10 months ago

PTGX: Lowering target price to $48.00

ACCESSWIRE

10 months ago

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

MT Newswires

10 months ago

Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target

ACCESSWIRE

10 months ago

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases

Insider Monkey

10 months ago

Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases

State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc

GuruFocus.com

10 months ago

State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc

Argus Research

a year ago

PTGX: Lowering target price to $46.00

MT Newswires

a year ago

TD Cowen Initiates Protagonist Therapeutics at Buy

Share on Social Networks: